Novo Nordisk is working with GoodRx to offer a month’s supply of Ozempic for $499, or about half the list price, for self-paying patients.
Ozempic, a drug approved for Type 2 diabetes, cardiovascular disease and kidney disease, has a list price of $997. Wegovy, which is indicated for weight loss, cardiovascular disease and liver disease, costs $1,349 for a four-week supply.
As of Aug. 18, all strengths of both GLP-1 medications are available for $499 per month for self-paying patients.
More than 70,000 U.S. retail pharmacies are participating in the offering, according to GoodRx and Novo Nordisk.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.